3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26
Walmart ($WMT), Johnson & Johnson ($JNJ), and Chevron ($CVX) are three Dividend Aristocrat stocks with a Strong Buy consensus rating on Wall Street...
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 13,307,056 | $3,379,593,434 | +44% | 1.01% |
| 2. | Markel Gayner Asset Management Tom Gayner | 610,800 | $155,124,875 | 1.18% | |
| 3. | RWC Asset Management Tord Stallvik (Ceo) | 262,139 | $66,575,442 | +2% | 2.52% |
| 4. | Levin Capital Strategies John A. Levin | 206,094 | $52,341,566 | -1% | 3.51% |
| 5. | 189,700 | $48,178,109 | +36% | 0.17% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $258.74 | 6,523 | $1,687,754.50 | 275,967 | 2026-08-05 | Filing | |
| $258.06 | 41,957 | $10,827,255.59 | 282,490 | 2026-08-05 | Filing | |
| $255.93 | 6,574 | $1,682,496.97 | 16,994 | 2026-08-06 | Filing | |
| $257.76 | 9,344 | $2,408,462.72 | 23,568 | 2026-08-06 | Filing | |
| $251.27 | 23,054 | $5,792,686.36 | 23,003 | 2026-07-20 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 212,098,264 | $53,866,596,264 | 0.8% | |
| 2. | 133,776,025 | $33,975,097,069 | 1.01% | |
| 3. | 21,683,347 | $5,506,919,975 | 0.9% | |
| 4. | 15,661,323 | $3,977,506,204 | 1.15% | |
| 5. | 10,539,098 | $2,703,293,314 | 0.86% |
News See All
3 Best ETFs to Invest In, According to the AI Analyst – 8/6/2026
Investors prefer exchange-traded funds (ETFs) to gain exposure to stocks across different sectors, bonds, and other asset classes. ETFs can generat...
3 Best Vanguard ETFs to Build Passive Income in Retirement
Many investors focus on building a large retirement portfolio. However, the bigger challenge is turning those savings into steady income. Vanguard ...
3 ‘Strong Buy’ Dividend Aristocrat Stocks for Dependable Income, 8/5/26
For investors seeking dependable dividend income, International Business Machines ($IBM), Johnson & Johnson ($JNJ), and Coca-Cola ($KO) stand out. ...
Broadcom Stock (AVGO) Falls as Goldman Sachs Removes It From the ‘Conviction List’
The bank sees the market rally broadening out beyond AI.
Jim Cramer Analyzes Johnson & Johnson (JNJ) After Surgical Robotics Milestone
Jim Cramer celebrated a dramatic pivot in market sentiment surrounding Johnson & Johnson (NYSE:JNJ) during Mad Money’s July 23 episode.
Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion.
Johnson & Johnson (JNJ) Raised Its Outlook. Is It the Better Healthcare Stock to Own After Earnings?
Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 billion, above analysts' average estimate of about $25.05 billion.
President Trump Loves Johnson & Johnson (JNJ), But Insiders Are Selling
Johnson & Johnson (NYSE:JNJ) is one of the health care names that showed up in President Donald Trump's financial disclosures released earlier this year.
Jim Cramer Said To Buy Johnson & Johnson (NYSE:JNJ)'s Shares - Here's What Happened Next
Healthcare giant Johnson & Johnson (NYSE:JNJ) is one of Jim Cramer's top healthcare stocks even though the shares have been lackluster.
Hedge Fund Resource Center